Phase III Trial of Dalcetrapib: Discontinued Due to Lack of Efficacy

ISSN： 1178-2595

Source： Pharmaceutical Medicine, Vol.26, Iss.4, 2012-08, pp. : 253-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase III Trial of Lapatinib: Discontinued due to Inferior Efficacy

Pharmaceutical Medicine, Vol. 26, Iss. 5, 2012-10 ,pp. : 321-325

Adis International

Access to resources Recommend Favorite

Phase III ATENA Trial of Exemestane Discontinued

By Sweetlove Mel

Pharmaceutical Medicine, Vol. 26, Iss. 1, 2012-02 ,pp. : 45-47

Adis International

Access to resources Recommend Favorite

Phase III Trial of Eprotirome: Discontinued for Safety Concerns

By Sweetlove Mel

Pharmaceutical Medicine, Vol. 26, Iss. 3, 2012-06 ,pp. : 185-187

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK) has discontinued enrolment into its phase III trial of the HIV entry inhibitor, aplaviroc [GW 873140]

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Dalcetrapib: a review of Phase II data

By Robinson Jennifer G

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 6, 2010-06 ,pp. : 795-805

Informa Healthcare

Access to resources Recommend Favorite